statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Companies Reporting Before The Bell
 Addex Therapeutics (NASDAQ:ADXN) is estimated to report earnings for its fourth quarter.
read more...

Earnings Scheduled For April 18, 2024

Addex Therapeutics Ltd (CH:ADXN) has released an update. Addex Therapeutics has partnered with investment firm Perceptive Advisors to launch Neuros...

Addex Launches Neurosterix with $63M for Neurological R&D

Addex receives CHF5M and 20% share of Neurosterix Perceptive Advisors leads $63M investment into Neurosterix Addex contributes portfolio of preclinical neuroscience assets and...

Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

Addex Therapeutics Ltd (NASDAQ:ADXN - Get Free Report) was the recipient of a significant growth in short interest in March. As of March 15th, there was short interest totalling 11,900 shares, a...

Addex Therapeutics Ltd (NASDAQ:ADXN) Short Interest Up 41.7% in March

Addex Therapeutics Ltd (NASDAQ:ADXN  Get Free Report) was the target of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling...

Addex Therapeutics Ltd (NASDAQ:ADXN) Short Interest Update

Geneva, Switzerland, January 9, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...

Addex to Present at the Swiss Equities Baader Conference

CEO to provide update on allosteric modulator pipeline clinical and preclinical development Geneva, Switzerland, January 5, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage...

Addex to Present at Biotech Showcase  2024

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

Volume	7,875.00
52-Wk High	$27.90
52-Wk Low	$5.00

ADXN Addex Therapeutics Ltd - ADR

About

Feed

News

Fundamentals